Obesity is amongst the most crowded pipelines in biotech, but sponsors in China and the West are building very different assets. I had Sleuth map 1,200+ active obesity assets from preclinical through approved and segment by primary development strategy and program origin. Two things stood out:

1. Chinese and Western drug development is indexing on different strategies

Amongst clinical stage assets (~470 programs), disclosed China-origin assets lean into “better incretins”, such as multi-agonist stacking or long-acting dosing. These stay within the traditional GLP-1 world.

Western programs tend to lean the other way, building toward what incretins don’t solve, to own the patients incretins struggle to keep (given ~60+% of patients discontinue GLP-1s within a year):

• Muscle-sparing weight loss (this is filling fast: Lilly / Versanis, Scholar Rock, Regeneron, GSK / Shian, China already in via RNAi, etc.)
• Oral delivery, for adherence and access
• Tolerability, the single biggest reason patients walk away

An important caveat: Sleuth does pull in proprietary or hard-to-source Chinese data, but overall program disclosure is a lot thinner – so the non-incretin gap is directional rather than exact.

2. The white space concentrates in the non-incretin world, but it’s uneven

If we zoom into the non-incretin programs and map them by (a) how clinically proven the science is and (b) how China-concentrated the activity is, we see:

• Muscle/activin and amylin are the crowded giants, with dozens of programs each
• The most clinically advanced pockets, FGF21, thyroid receptor beta, and bile-acid, sit high on Chinese origin, so the West would enter those as a fast-follower
• The genuinely open, China-light pockets are smaller and earlier: MC4R/melanocortin, NPY/PYY, PTP1B, NLRP3, mitochondrial uncouplers

That last point is important for positioning – because the pipeline activity is preclinical, it’s critical to map data points scattered across regional conferences, patents and company disclosures. If you’re a biotech CEO shaping a next-gen obesity asset, it’s useful to see the field in aggregate, but more important to personalize that analysis to your program. That’s the kind of positioning work we dig into.